Min Zhao

Min Zhao

Auto-generated profile, based on publicly available information

Min Zhao

Nanjing University of Chinese Medicine, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YDYuxin Dai
Yuxin Dai
QLQiulu Lu
Qiulu Lu
PLPeiyi Li
Peiyi Li
JZJunyu Zhu
Junyu Zhu
JJJiaxin Jiang
Jiaxin Jiang
MZMin Zhao
Min Zhao

21 October 2019 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
MZMin Zhao
Min Zhao
YBYaoyao Bian
Yaoyao Bian
LYLi-Li Yang
Li-Li Yang
YCYan-Qi Chen
Yan-Qi Chen
YWYa-Jie Wang
Ya-Jie Wang
ZLzeng li
zeng li
Intraperitoneal adhesion is a common complication after abdominal surgery, which seriously affects the quality of life of patients. HuoXueTongFu Formula (HXTF) plays an important role in the prevention and treatment of intraperitoneal adhesions. However, the molecular-related mechanisms are still not fully known. In this study, the model of Intrapetitoneal adhesion was established by cecum abrasion and treated with HXTF for one week. RAW264.7 cells were given LPS, IFN-γ, IL-4, HXTF-medicated serum, and PPAR-γ agonist/antagonist, respectively. Histopathology, flow cytometry, ELISA, real-time PCR, and Western blotting were used to further detect the related protein, M1/M2 polarization tendency, and PPAR-γ nuclear translocation. The deposition of collagen fibres reduced in the local area of rats after the operation with HXTF treatment. Similar to IL-4, HXTF induced a tendency for macrophages to polarize toward M2 and promoted peroxisome proliferator-activated receptor-gamma (PPAR-γ) nuclear translocation. Furthermore, the use of HXTF and PPAR-γ agonists downregulated macrophage M1 polarization-related factors IL-1, IL-6, and TNF-alpha and upregulated M2 polarization-related factors IL-4, IL-10, and TGF-beta 1. Meanwhile, the use of HXTF and PPAR-γ agonists downregulated the SOCS3/JAK2/STAT1 pathway and activated the SOCS1/STAT6/PPAR-γ pathway. These results show that HXTF may reduce intraperitoneal adhesion by inducing macrophage M2 polarization and regulating the SOCS/JAK2/STAT/PPAR-γ pathway.

17 May 2023 in Phytomedicine
Verified
Journal Article
Closed access
WTWeiwei Tao
Weiwei Tao
GYGuangda Yao
Guangda Yao
QYQiyu Yue
Qiyu Yue
CXChunyan Xu
Chunyan Xu
YHYue Hu
Yue Hu
YYYue Yu
Yue Yu

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
LYLili Yang
Lili Yang
ZLZhengjun Li
Zhengjun Li
YCYao Chen
Yao Chen
FCFeiyan Chen
Feiyan Chen
HSHaopeng Sun
Haopeng Sun
YBYaoyao Bian
Yaoyao Bian
Postoperative peritoneal adhesion (PPA) is a major clinical complication after open surgery or laparoscopic procedure. Ligustrazine is the active ingredient extracted from the natural herb Ligusticum chuanxiong Hort, which has promising antiadhesion properties. This study is aimed at revealing the underlying mechanisms of ligustrazine in preventing PPA at molecular and cellular levels. Both rat primary peritoneal mesothelial cells (PMCs) and human PMCs were used for analysis in vitro. Several molecular biological techniques were applied to uncover the potential mechanisms of ligustrazine in preventing PPA. And molecular docking and site‐directed mutagenesis assay were used to predict the binding sites of ligustrazine with PPARγ. The bioinformatics analysis was further applied to identify the key pathway in the pathogenesis of PPA. Besides, PPA rodent models were prepared and developed to evaluate the novel ligustrazine nanoparticles in vivo. Ligustrazine could significantly suppress hypoxia‐induced PMC functions, such as restricting the production of profibrotic cytokines, inhibiting the expression of migration and adhesion‐associated molecules, repressing the expression of cytoskeleton proteins, restricting hypoxia‐induced PMCs to obtain myofibroblast‐like phenotypes, and reversing ECM remodeling and EMT phenotype transitions by activating PPARγ. The antagonist GW9662 of PPARγ could restore the inhibitory effects of ligustrazine on hypoxia‐induced PMC functions. The inhibitor KC7F2 of HIF‐1α could repress hypoxia‐induced PMC functions, and ligustrazine could downregulate the expression of HIF‐1α, which could be reversed by GW9662. And the expression of HIF‐1α inhibited by ligustrazine was dramatically reversed after transfection with si‐SMRT. The results showed that the benefit of ligustrazine on PMC functions is contributed to the activation of PPARγ on the transrepression of HIF‐1α in an SMRT‐dependent manner. Molecular docking and site‐directed mutagenesis tests uncovered that ligustrazine bound directly to PPARγ, and Val 339/Ile 341 residue was critical for the binding of PPARγ to ligustrazine. Besides, we discovered a novel nanoparticle agent with sustained release behavior, drug delivery efficiency, and good tissue penetration in PPA rodent models. Our study unravels a novel mechanism of ligustrazine in preventing PPA. The findings indicated that ligustrazine is a potential strategy for PPA formation and ligustrazine nanoparticles are promising agents for preclinical application.

18 August 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
QYQiyu Yue
Qiyu Yue
ZLZhengjun Li
Zhengjun Li
YDYuxin Du
Yuxin Du
XHXiaobei Hao
Xiaobei Hao
HHHua Huang
Hua Huang
MZMin Zhao
Min Zhao

8 October 2026 in Phytotherapy Research
Verified
Journal Article
Open access
QYQiyu Yue
Qiyu Yue
CYChen Yong
Chen Yong
XWXinran Wang
Xinran Wang
YSYang Shu
Yang Shu
MYMin Yao
Min Yao
EZEnchao Zhou
Enchao Zhou
Astragaloside IV (AS‐IV) has demonstrated efficacy in ameliorating proteinuria and attenuating renal tubular damage in preclinical diabetic nephropathy (DN) models. Despite these multi‐target benefits, the molecular mechanisms underlying its podocyte‐protective effects remain largely uncharacterized, particularly its potential epigenetic regulatory capacity within glomerular cells. This study aimed to test the hypothesis that AS‐IV protects against DN by activating the deacetylase sirtuin 6 (SIRT6). Specifically, AS‐IV activates SIRT6, which deacetylates Histone H3 at Lysine 9 (H3K9) at the Notch1 promoter, thereby suppressing Notch1 expression. This suppression is expected to enhance autophagy and reduce apoptosis, ultimately repairing renal filtration barrier injury. A murine model of DN was induced with streptozotocin and a high‐fat diet. To simulate diabetic damage, MPC‐5 podocytes were subjected to high glucose (HG, 33 mM). Renal function metrics were extensively evaluated, and glomerular histopathological and ultrastructural changes were assessed by hematoxylin and eosin staining and electron microscopy. Subsequently, downstream mechanisms involving podocyte autophagy and apoptosis were investigated by immunofluorescence staining and Western blotting. To confirm that SIRT6 directly regulates Notch1 transcription via histone deacetylation, our study utilized chromatin immunoprecipitation (ChIP). Our results showed that AS‐IV treatment alleviated renal biochemical and pathological abnormalities in DN mice and attenuated podocyte injury, evidenced by restoring nephrin and podocin expression and reducing glomerular basement membrane thickness ( p < 0.01). Functionally, AS‐IV treatment reversed HG‐induced podocyte apoptosis and autophagy dysfunction ( p < 0.01). Mechanistically, AS‐IV was confirmed to directly bind to SIRT6 (Kd = 0.164 μM). ChIP assays demonstrated increased SIRT6 occupancy and consequently reduced H3K9ac enrichment at the Notch1 promoter ( p < 0.01). In summary, AS‐IV may ameliorate DN by activating the SIRT6/H3K9ac/ Notch1 epigenetic axis, providing a strong molecular basis for AS‐IV as a promising therapeutic agent against DN.